title: Mumps antibody in the Thai population 17 years after the universal measles mumps rubella vaccination program.
abstract: BACKGROUND
  mumps vaccination implementation in the form of MMR - measles, mumps, and rubella) in Thailand for first-grade school students since 1997 and for infants 9-12 months of age since 2010 resulted in a dramatic decline in the incidence of and deaths from mumps. However, there has been a resurgence of mumps outbreaks in Thailand, even in vaccinated populations.
  
  
  METHODS
  We aimed to determine the current seroprevalence of IgG antibodies to mumps in those 0-60 years of age from four different geographic areas of Thailand, and compare the results with our previous serosurvey in 2004.
  
  
  RESULTS
  Seropositivity rates in children 0-7 years of age increased significantly from 45.8% in 2004 to 72.3% in 2014 after the launch of the MMR vaccine for infants. In the 8-14-year age group who had received one dose of mumps vaccination, the seropositivity rate was 66.7%. In the 15-19-year age group the seropositivity rate was the lowest, at 52.5%.
  
  
  CONCLUSIONS
  Our findings correspond well with the vaccination schedules, as the highest seropositivity rate was found in children between 0 and 7 years of age. For those older than 7, there was a decline in seropositivity rate despite good vaccine coverage and reached its lowest in the 15-19-year age group. This suggested that certain population groups might be incompletely vaccinated, or the humoral immunity provided by vaccination gradually declined over time.
  
  
  CONCLUSIONS
  We recommend a booster dose of MMR vaccine for Thai adolescents in order to prevent future mumps outbreaks.
authors.affiliation: Faculty of Medicine, Chulalongkorn University, Pathumwan, Bangkok, Thailand. varisara.n@gmail.com.
authors.forename: Varisara
authors.initials: V
authors.lastname: Ngaovithunvong
authors.forename: Nasamon
authors.initials: N
authors.lastname: Wanlapakorn
authors.forename: Lita
authors.initials: L
authors.lastname: Tesapirat
authors.forename: Narrissara
authors.initials: N
authors.lastname: Suratannon
authors.forename: Yong
authors.initials: Y
authors.lastname: Poovorawan
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000914:Antibodies, Viral / Q000097:blood*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D017589:Immunization Programs; D007074:Immunoglobulin G / Q000097:blood; D007223:Infant; D008297:Male; D022542:Measles-Mumps-Rubella Vaccine / Q000008:administration & dosage*; D008875:Middle Aged; D009107:Mumps / Q000517:prevention & control*; D009109:Mumps virus / Q000276:immunology*; D016036:Seroepidemiologic Studies; D013785:Thailand / Q000453:epidemiology; D055815:Young Adult
chemical_list: D000914:Antibodies, Viral; D007074:Immunoglobulin G; D022542:Measles-Mumps-Rubella Vaccine